Category: 64-10-8

Authors Quattrini, L; Coviello, V; Sartini, S; Di Desidero, T; Orlandi, P; Ke, YY; Liu, KL; Hsieh, HP; Bocci, G; La Motta, C in NATURE PUBLISHING GROUP published article about AURORA KINASE; MEK INHIBITION; DRUG DESIGN; MECHANISMS; RESISTANCE; BRAF; KIT; IDENTIFICATION; VEMURAFENIB; SIMULATION in [Quattrini, Luca; Coviello, Vito; Sartini, Stefania; La Motta, Concettina] Univ Pisa, Dipartimento Farm, Via Bonanno 6, I-56126 Pisa, Italy; [Di Desidero, Teresa; Orlandi, Paola; Bocci, Guido] Univ Pisa, Dipartimento Med Clin & Sperimentale, Via Roma 55, I-56126 Pisa, Italy; [Ke, Yi-Yu; Liu, Kai-Lun; Hsieh, Hsing-Pang] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, 35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan in 2019.0, Cited 46.0. Safety of 1-Phenylurea. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8

Melanoma is the most serious form of skin cancer but its medication is still far from being safe and thoroughly effective. The search of novel therapeutic approaches represents therefore a health emergency to push through eagerly. In this study, we describe a novel class of dual c-Kit/Aur inhibitors, characterized by a 1,2,4-triazole core and developed by a structure-based optimization of a previously developed hit, and report the evidence of their significance as drug candidates for the treatment of melanoma. Compound 6a, merging the best inhibitory profile against the target kinases, showed anti-proliferative efficacy against the human melanoma cell lines A2058, expressing the BRAFV600D mutation, and WM266-4, expressing BRAF V600E. Significantly, it displayed also a highly synergistic profile when tested in combination with vemurafenib, thus proving its efficacy not only per se but even in a combination therapy, which is nowadays acknowledged as the cornerstone approach of the forthcoming tumour management.

Welcome to talk about 64-10-8, If you have any questions, you can contact Quattrini, L; Coviello, V; Sartini, S; Di Desidero, T; Orlandi, P; Ke, YY; Liu, KL; Hsieh, HP; Bocci, G; La Motta, C or send Email.. Safety of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

In 2020.0 J MINIM INVAS GYN published article about MULTIPLE IMPUTATION; FLEXIBLE TOOL; WOMEN; HYSTERECTOMY; TRENDS in [Matsushita, Tomomi] Johns Hopkins Bloomberg Sch Publ Hlth, 615 North Wolfe St, Baltimore, MD 21205 USA; [Matsushita, Tomomi; Sekizawa, Akihiko] Showa Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan; [Jacobs, Lisa K.] Dept Surg, Tokyo, Japan; Johns Hopkins Univ, Sch Med, Baltimore, MD USA in 2020.0, Cited 25.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. SDS of cas: 64-10-8

Study Objective: To investigate whether the rate of increase in the performance of abdominal myomectomy over a laparoscopic approach after the US Food and Drug Administration (FDA) safety communication regarding morcellator use for myomectomy differs among races. Design: Retrospective cohort study. Setting: The American College of Surgeons National Surgical Quality Improvement data. Patients: Patients aged 18 to 55 years who underwent either laparoscopic or abdominal myomectomy, excluding malignant cases, emergency cases, operations performed by nongynecologic specialists, and cases in which myomectomy was performed during cesarean section. Interventions: None. Measurements and Main Results: The odds ratios of abdominal myomectomy over laparoscopic myomectomy before and after the release of the FDA communication were calculated in 3 race categories: white, African American, and other races. In a logistic regression analysis adjusted for possible confounders, including all races, the odds ratio of abdominal myomectomy before and after the FDA communication was 1.30 (95% confidence interval [CI], 1.20-1.41; p <. 001). In a logistic regression analysis with a product term of FDA communication exposure and race as a possible effect modifier, the African American population showed a significantly greater change in the odds of abdominal myomectomy over laparoscopic myomectomy in comparison with the white population (1.22; 95% CI, 1.02-1.47; p =.03). In contrast, other races showed no significant change (.83; 95% CI,.64-1.08; p =.17). Conclusion: After the FDA communication, the odds ratio of abdominal myomectomy was disproportionately increased in the African American population. (C) 2019 Published by Elsevier Inc. on behalf of AAGL. Bye, fridends, I hope you can learn more about C7H8N2O, If you have any questions, you can browse other blog as well. See you lster.. SDS of cas: 64-10-8

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about LIQUID-CHROMATOGRAPHY; CLASSIFICATION; PURIFICATION; SELECTIVITY; RETENTION; SYSTEM; SFC, Saw an article supported by the . Published in ELSEVIER in AMSTERDAM ,Authors: Jiang, DS; Ke, YX; Cai, JF; Zhang, HH; Fu, Q; Jin, Y; Liang, XM. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea. Recommanded Product: 64-10-8

In recent years, supercritical fluid chromatography (SFC) has become a powerful tool in modern analytical chemistry, and the diversity of stationary phases in SFC promotes phenyl-type phases to confront with a significant resurgence of interest. In this paper, a series of phenyl-type stationary phases with different substituted benzenes involving N-propylbenzamide (PB), 4-fluoro-N-propylbenzamide (PB-F), and 4-ethyl-N-propylbenzamide (PB-ET) were synthesized. Retention mechanism of these phases in SFC was investigated using a linear solvation energy relationship (LSER) model. The phenyl-type stationary phases with all positive parameters can provide all types of interaction, typically involving hydrogen bonding, dipole-dipole and dispersive interactions. The different benzene’s substituents of the stationary phases mainly affected their hydrogen bonding and dipole-dipole interactions, which could be reflected by the angle between the solvation vectors to some extent. The k-k plot showed that the selectivity difference of phenyl-type stationary phases was closely related to the type of solute. Thus, based on twenty-five natural phenolic compounds, two systems with high orthogonality (63.49%) were constructed using three columns, namely phenyl column (PHE) x PB-F and PB x PB-F. Finally, after investigating the influence of chromatographic conditions, ten flavonoids could be separated by using PB, PB-F and PHE columns in SFC. (C) 2019 Published by Elsevier B.V.

Bye, fridends, I hope you can learn more about C7H8N2O, If you have any questions, you can browse other blog as well. See you lster.. Recommanded Product: 64-10-8

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

An article EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer WOS:000462996800012 published article about ACQUIRED-RESISTANCE; CAPRI-GOIM; PLUS CETUXIMAB; INHIBITOR; MUTATIONS in [Martini, Giulia; Cardone, Claudia; Vitiello, Pietro Paolo; Belli, Valentina; Napolitano, Stefania; Troiani, Teresa; Ciardiello, Davide; Della Corte, Carminia Maria; Morgillo, Floriana; Matrone, Nunzia; Ciardiello, Fortunato; Martinelli, Erika] Univ Campania L Vanvitelli, Med Oncol, Dept Precis Med, Via Pansini 5, I-80131 Naples, Italy; [Sforza, Vincenzo] Fdn Pascale, IRCCS, Ist Nazl Tumori, Dept Clin Expt Thorac Oncol, Naples, Italy; [Papaccio, Gianpaolo; Desiderio, Vincenzo; Tirino, Virginia] Univ Campania Luigi Vanvitelli Napoli, Dept Expt Med, Naples, Italy; [Paul, Mariel C.; Moreno-Viedma, Veronica; Sibilia, Maria] Med Univ Vienna, Comprehens Canc Ctr, Dept Med 1, Inst Canc Res, Borschkegasse 8a, Vienna, Austria; [Normanno, Nicola; Rachiglio, Anna Maria] Fdn Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy; [Maiello, Evaristo; Latiano, Tiziana Pia; Rizzi, Daniele] Hosp Casa Sollievo Della Sofferenza San Giovanni, Med Oncol, San Giovanni Rotondo, Italy; [Signoriello, Giuseppe] Univ Campania L Vanvitelli, Biostat, Dipartimento Salute Mentale & Fis & Med Prevent, Naples, Italy in 2019.0, Cited 24.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Application In Synthesis of 1-Phenylurea

The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorectal cancer. We studied activation of EPHA2 in a panel of human colorectal cancer cell lines sensitive or resistant to anti-EGFR drugs. The in vitro and in vivo effects of ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab treatment were tested. Fonnalin-fixed paraffin-embedded tumor specimens from 82 RAS wild-type (WV) metastatic colorectal cancer patients treated with FOLFIRI + cetuximab as first-line therapy in the CAPRI-COIM trial were assessed for EPHA2 expression by immunohistochemistry and correlated with treatment efficacy. EPHA2 was differentially activated in colorectal cancer cell lines. Combined treatment with ALW-II-41-27 plus cetuximab reverted primary and acquired resistance to cetuximab, causing cell growth inhibition, inducing apoptosis and cell-cycle G1-G2 arrest. In tumor xenograft models, upon progression to cetuximab, ALW-II-41-27 addition significantly inhibited tumor growth. EPHA2 protein expression was detected in 55 of 82 tumor samples, frequently expressed in less-differentiated and left-sided tumors. High levels of EPHA2 significantly correlated with worse progression-free survival [8.6 months; confidence interval (CI) 95%, 6.4-10.8; vs. 12.3 months; CI 95%, 10.4-14,2; P = 0.03] and with increased progression rate (29% vs. 9%, P = 0.02). A specific EPHA2 inhibitor reverts in vitro and in vivo primary and acquired resistance to anti-ECFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.

Application In Synthesis of 1-Phenylurea. Welcome to talk about 64-10-8, If you have any questions, you can contact Martini, G; Cardone, C; Vitiello, PP; Belli, V; Napolitano, S; Troiani, T; Ciardiello, D; Della Corte, CM; Morgillo, F; Matrone, N; Sforza, V; Papaccio, G; Desiderio, V; Paul, MC; Moreno-Viedma, V; Normanno, N; Rachiglio, AM; Tirino, V; Maiello, E; Latiano, TP; Rizzi, D; Signoriello, G; Sibilia, M; Ciardiello, F; Martinelli, E or send Email.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about CALCIUM-CHANNEL BLOCKERS; HETEROCYCLIC CARBENE; KINETIC RESOLUTION; STEREOSELECTIVE-SYNTHESIS; COOPERATIVE CATALYSIS; ASYMMETRIC-SYNTHESIS; REDOX AMIDATIONS; ACID-ESTERS; ALDEHYDES; POTENT, Saw an article supported by the University of Ferrara (fondi FAR). Application In Synthesis of 1-Phenylurea. Published in WILEY-V C H VERLAG GMBH in WEINHEIM ,Authors: Brandolese, A; Ragno, D; Leonardi, C; Di Carmine, G; Bortolini, O; De Risi, C; Massi, A. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea

The oxidative N-acylation reaction of 3,4-dihydropyrimidin-2-(1H)-ones (DHPMs) with enals and N-heterocyclic carbene (NHC) catalysts is described. The reaction proceeds in the presence of quinone oxidant without additional acyl transfer agents and in the asymmetric variant produces pharmaceutically relevant N3-acylated products with good-to-moderate enantioselectivity.

Welcome to talk about 64-10-8, If you have any questions, you can contact Brandolese, A; Ragno, D; Leonardi, C; Di Carmine, G; Bortolini, O; De Risi, C; Massi, A or send Email.. Application In Synthesis of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

I found the field of Oncology very interesting. Saw the article Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer published in 2019.0. Quality Control of 1-Phenylurea, Reprint Addresses Grossi, F (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy.. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea

Background: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced nonesmall cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression. Methods: Pretreated patients with advanced non-squamous NSCLC received nivolumab at 3 mg/kg every 2 weeks up to 24 months. Efficacy data (investigator-assessed tumour response, progression date and survival) and safety data were collected. Findings: 1588 patients were treated across 153 Italian centres. Overall response rate and disease control rate were 18% and 44%, respectively; median overall survival (OS) was 11.3 months (95% CI: 10.2-12.4). Elderly patients (>= 70 n = 522; >= 75 n = 232) achieved outcomes similar to the global study population; patients with CNS metastases (n = 409) had an OS of 8.6 months (95% CI: 6.4-10.8), and a 1-year OS rate of 43%. Nivolumab was administered beyond progression to 276 patients (26%), 57 of whom achieved subsequent disease control; the median OS of patients receiving nivolumab beyond progression was 16.2 months (95% CI: 14.0-18.4), while 1-year OS rate was 62%. Interpretation: To date, this is the largest clinical experience with nivolumab in a real-world setting. Our data support its use in clinical practice for pretreated non-squamous NSCLC, including patients with older age or CNS metastases. (C) 2019 Elsevier Ltd. All rights reserved.

Quality Control of 1-Phenylurea. Welcome to talk about 64-10-8, If you have any questions, you can contact Grossi, F; Genova, C; Crino, L; Delmonte, A; Turci, D; Signorelli, D; Passaro, A; Parra, HS; Catino, A; Landi, L; Gelsomino, F; Tiseo, M; Puppo, G; Roila, F; Ricciardi, S; Tonini, G; Cognetti, F; Toschi, L; Tassinari, D; Scoppola, A; Giannarelli, D; Cortesi, E or send Email.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Recently I am researching about MICROFIBRILLATED CELLULOSE; POLYMER NANOCOMPOSITES; ELASTIC-MODULUS; MECHANICAL-PROPERTIES; CRYSTALLINE REGIONS; SURFACE; GREEN; DISSOLUTION; BIOCOMPOSITES; NANOCELLULOSE, Saw an article supported by the National Agriculture and Food Research Organization (NARO) Bio-oriented Technology Research Advancement Institution; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17H06238]; DIC Corporation; Daio Paper Corporation. COA of Formula: C7H8N2O. Published in AMER CHEMICAL SOC in WASHINGTON ,Authors: Sakakibara, K; Moriki, Y; Tsujn, Y. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea

Production of nanocomposites from macro-scale materials in situ in a melting compounder is highly desirable yet challenging. In this study, we develop a highly efficient approach for the preparation of cellulose nanofiber (CNF)-reinforced high-density polyethylene (HDPE) composite materials from as-received wood pulp fibers, in which nanofibrillation-assisting plasticizers (urea and urea derivatives) and a diblock copolymer dispersant are used. The most effective plasticizer is urea, which plays a crucial role in producing CNF with less fragmentation during the kneading step, owing to the plasticization/nanofibrillation and the reaction with hydroxyl groups of cellulose fibers into a carbamate. The diblock copolymer as a dispersant enables the stabilization of the appropriate dispersion of the produced CNF in nonpolar HDPE. The resulting composites exhibit significantly improved mechanical properties, including a 6.9-fold increase in the Youngs modulus with 10 wt % loading of wood pulp fibers over that of neat HDPE.

COA of Formula: C7H8N2O. Welcome to talk about 64-10-8, If you have any questions, you can contact Sakakibara, K; Moriki, Y; Tsujn, Y or send Email.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Shiota, M; Endo, S; Fujimoto, N; Tsukahara, S; Ushijima, M; Kashiwagi, E; Takeuchi, A; Inokuchi, J; Uchiumi, T; Eto, M in [Shiota, Masaki; Tsukahara, Shigehiro; Ushijima, Miho; Kashiwagi, Eiji; Takeuchi, Ario; Inokuchi, Junichi; Eto, Masatoshi] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan; [Endo, Satoshi] Gifu Pharmaceut Univ, Dept Biopharmaceut Sci, Lab Biochem, Gifu, Japan; [Fujimoto, Naohiro] Univ Occupat & Environm Hlth, Sch Med, Dept Urol, Kitakyushu, Fukuoka, Japan; [Tsukahara, Shigehiro; Uchiumi, Takeshi] Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Fukuoka, Japan published Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy in 2020.0, Cited 36.0. Quality Control of 1-Phenylurea. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8.

Objective: Androgen metabolism is a key component in therapeutic resistance to androgen deprivation therapy (ADT). This study aimed to reveal the significance of genetic polymorphisms in genes involved in androgen metabolism, including CYP17A1, AKR1C3, and HSD17B, on serum testosterone levels during ADT, as well as the prognosis of men undergoing ADT for metastatic prostate cancer (CaP). Materials and methods: This study included 104 Japanese patients with metastatic CaP, for whom serum testosterone data during ADT were available for 80 patients. The association of CYP17A1 (rs743572), AKR1C3 (rs12529), HSD17B1 (rs605059), HSD17B3 (rs2066479), and HSD17B4 (rs7737181) with serum testosterone levels during ADT and prognosis (progression-free survival and overall survival) was examined. Enzymatic activity in AKR1C3 H5Q was examined using recombinant protein. Results: Homozygous wild-type (GG allele; median [interquartile range], 12.0 ng/ml [8.0-19.0 ng/ml]) AKR1C3 rs12529 was associated with higher serum testosterone levels during ADT compared with variant-type (GC/CC alleles; median [interquartile range], 9.0 ng/ml [6.4-10.8 ng/ml]). Consistently, variant-type (GC/CC alleles) AKR1C3 rs12529 showed significantly lower risk of progression (hazard ratio [95% confidence interval], 0.47 [0.24-0.96], P = 0.039) compared with homozygous wild-type (GG allele) on multivariate analysis. Meanwhile, other genetic variations were associated with neither serum testosterone during ADT nor prognosis. Enzyme activity of wild-type AKR1C3 was comparable to the H5Q mutant. Conclusions: Taken together, this study demonstrated that AKR1C3 polymorphism, which was associated with serum testosterone levels during ADT, may be a prognostic factor of the progression to castration-resistant prostate cancer in Japanese men with metastatic CaP. (C) 2020 Elsevier Inc. All rights reserved.

Welcome to talk about 64-10-8, If you have any questions, you can contact Shiota, M; Endo, S; Fujimoto, N; Tsukahara, S; Ushijima, M; Kashiwagi, E; Takeuchi, A; Inokuchi, J; Uchiumi, T; Eto, M or send Email.. Quality Control of 1-Phenylurea

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

I found the field of Oncology; Urology & Nephrology very interesting. Saw the article Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy published in 2020.0. Quality Control of 1-Phenylurea, Reprint Addresses Shiota, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan.. The CAS is 64-10-8. Through research, I have a further understanding and discovery of 1-Phenylurea

Objective: Androgen metabolism is a key component in therapeutic resistance to androgen deprivation therapy (ADT). This study aimed to reveal the significance of genetic polymorphisms in genes involved in androgen metabolism, including CYP17A1, AKR1C3, and HSD17B, on serum testosterone levels during ADT, as well as the prognosis of men undergoing ADT for metastatic prostate cancer (CaP). Materials and methods: This study included 104 Japanese patients with metastatic CaP, for whom serum testosterone data during ADT were available for 80 patients. The association of CYP17A1 (rs743572), AKR1C3 (rs12529), HSD17B1 (rs605059), HSD17B3 (rs2066479), and HSD17B4 (rs7737181) with serum testosterone levels during ADT and prognosis (progression-free survival and overall survival) was examined. Enzymatic activity in AKR1C3 H5Q was examined using recombinant protein. Results: Homozygous wild-type (GG allele; median [interquartile range], 12.0 ng/ml [8.0-19.0 ng/ml]) AKR1C3 rs12529 was associated with higher serum testosterone levels during ADT compared with variant-type (GC/CC alleles; median [interquartile range], 9.0 ng/ml [6.4-10.8 ng/ml]). Consistently, variant-type (GC/CC alleles) AKR1C3 rs12529 showed significantly lower risk of progression (hazard ratio [95% confidence interval], 0.47 [0.24-0.96], P = 0.039) compared with homozygous wild-type (GG allele) on multivariate analysis. Meanwhile, other genetic variations were associated with neither serum testosterone during ADT nor prognosis. Enzyme activity of wild-type AKR1C3 was comparable to the H5Q mutant. Conclusions: Taken together, this study demonstrated that AKR1C3 polymorphism, which was associated with serum testosterone levels during ADT, may be a prognostic factor of the progression to castration-resistant prostate cancer in Japanese men with metastatic CaP. (C) 2020 Elsevier Inc. All rights reserved.

Quality Control of 1-Phenylurea. Bye, fridends, I hope you can learn more about C7H8N2O, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem

Quality Control of 1-Phenylurea. Authors Wang, CC; Qu, YL; Liu, XH; Ma, ZW; Yang, B; Liu, ZJ; Chen, XP; Chen, YJ in AMER CHEMICAL SOC published article about in [Wang, Chuan-Chuan; Ma, Zhi-Wei; Liu, Zhi-Jing; Chen, Xiao-Pei] Henan Univ Anim Husb & Econ, Fac Sci, Zhengzhou 450044, Henan, Peoples R China; [Wang, Chuan-Chuan; Yang, Bo] Zhengzhou Univ, Coll Chem, Zhengzhou 450001, Henan, Peoples R China; [Qu, Ya-Li; Liu, Xue-Hua] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China; [Chen, Ya-Jing] Zhengzhou Univ, Minist Educ China, Sch Pharmaceut Sci, Key Lab Adv Drug Preparat Technol, Zhengzhou 450001, Henan, Peoples R China; [Chen, Ya-Jing] Zhengzhou Univ, Coinnovat Ctr Henan Prov New Drug R&D & Preclin S, Zhengzhou 450001, Henan, Peoples R China in 2021.0, Cited 57.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8

The convenient preparation of N2-unprotected five-membered cyclic guanidines was achieved through a cascade [3 + 2] cycloaddition between organo-cyanamides and alpha-haloamides under mild conditions in good to excellent yields (up to 99%). The corresponding cyclic guanidines could be easily transformed into hydantoins via hydrolysis.

Quality Control of 1-Phenylurea. Bye, fridends, I hope you can learn more about C7H8N2O, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem